The acquired immune? deficiency syndrome (AIDS) is characterized by a progressive depletion? of CD4 lymphocytes. The causative agent of AIDS, the human? immunodeficiency virus (HIV) is a cytopathic retrovirus. Although the? mechanisms of CD4 cell loss in HIV-infected people remains unclear,? recent data indicate the direct cell killing of infected cells by HIV? itself is likely responsible. An accessory gene of HIV, the vpr gene,? plays an important role in the cytopathic effect of HIV. In the? presence of an intact vpr gene, cultures of infected cells are nearly? completely killed, while cultures infected with a virus that has a? mutated vpr gene survive and replicate with the same kinetics as? uninfected cells. Those cells that survive infection with a wild-type? virus contain vpr genes with mutations. Furthermore, expression of Vpr? itself alters cell cycle progression by causing cells to accumulate in? G2/M. Vpr also plays another role in the virus life-cycle by allowing? the pre-integration complex to enter the nucleus of infected cells? before mitosis. This property allows HIV to infect terminally? differentiated macrophages, an important reservoir of virus in the body.? In this application, we seek to understand the mechanism of action of? Vpr. Ultimately, we hope to determine if Vpr plays a role in the? decline of CD4 cells during AIDS progression. Specifically, we will use? a genetic screen for vpr mutations as well as site-directed mutations? to determine the correlation between the different functions of Vpr.? This will allow us to make models of the roles of Vpr in HIV? pathogenesis. We will also characterize the effects of Vpr and Vpx of? HIV-2 on cell proliferation. Next, we will characterize the cell cycle? stage(s) affected by Vpr, and analyze the relationship between normal? cell cycle controls and Vpr function. We will then determine the? effects of Vpr in primary cells, and specifically determine how Vpr? influences the half-life of lymphocytes and macrophages. Finally, we? will use a screen for suppressors of the toxic effects of Vpr in yeast? to Identify host cell targets of Vpr. In this application, we seek to? understand the mechanism of action of Vpr. Ultimately, we hope to? determine if Vpr plays a role in the decline of CD4 cells during AIDS? progression. Specifically, we will use a genetic screen for vpr? mutations as well as site-directed mutations to determine the? correlation between the different functions of Vpr. This will allow us? to make models of the roles of Vpr in HIV pathogenesis. We will also? characterize the effects of Vpr and Vpx of HIV-2 on cell proliferation.? Next, we will characterize the cell cycle stage(s) affected by Vpr, and? analyze the relationship between normal cell cycle controls and Vpr? function. We will then determine the effects of Vpr in primary cells,? and specifically determine how Vpr influences the half-life of? lymphocytes and macrophages. Finally, we will use a screen for? suppressors of the toxic effects of Vpr in yeast to Identify host cell? targets of Vpr.?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI030927-17
Application #
7229009
Study Section
Special Emphasis Panel (NSS)
Program Officer
Young, Janet M
Project Start
1991-08-01
Project End
2011-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
17
Fiscal Year
2007
Total Cost
$480,567
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Malfavon-Borja, Ray; Sawyer, Sara L; Wu, Lily I et al. (2013) An evolutionary screen highlights canonical and noncanonical candidate antiviral genes within the primate TRIM gene family. Genome Biol Evol 5:2141-54
Tareen, Semih U; Emerman, Michael (2011) Human Trim5? has additional activities that are uncoupled from retroviral capsid recognition. Virology 409:113-20
Tareen, Semih U; Sawyer, Sara L; Malik, Harmit S et al. (2009) An expanded clade of rodent Trim5 genes. Virology 385:473-83
Voronin, Yegor; Holte, Sarah; Overbaugh, Julie et al. (2009) Genetic drift of HIV populations in culture. PLoS Genet 5:e1000431
OhAinle, Molly; Kerns, Julie A; Li, Melody M H et al. (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4:249-59
Lin, Tsai-Yu; Emerman, Michael (2008) Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1. Virology 379:335-41
Sawyer, Sara L; Emerman, Michael; Malik, Harmit S (2007) Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog 3:e197
Voronin, Yegor; Chohan, Bhavna; Emerman, Michael et al. (2007) Primary isolates of human immunodeficiency virus type 1 are usually dominated by the major variants found in blood. J Virol 81:10232-41
Yamashita, Masahiro; Emerman, Michael (2006) Retroviral infection of non-dividing cells: old and new perspectives. Virology 344:88-93

Showing the most recent 10 out of 25 publications